Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: "Klaus Okkenhaug" Clear advanced filters
  • The kinase PI(3)Kδ is shown to be required for the immunosuppressive function of regulatory T cells; inactivation of PI(3)Kδ in these cells leads to enhanced cytotoxic T-cell function and restricts tumour growth and metastasis in a variety of mouse tumour models.

    • Khaled Ali
    • Dalya R. Soond
    • Bart Vanhaesebroeck
    Research
    Nature
    Volume: 510, P: 407-411
  • Idelalisib, the first PI3Kδ inhibitor in clinical use, has excellent activity in patients with chronic lymphocytic leukaemia and indolent B-cell lymphomas, heralding a new era of targeted therapy for these types of cancer. Idelalisib intercepts critical communications between B cells and the microenvironment, including B-cell receptor signalling and chemokine networks.

    • Jan A. Burger
    • Klaus Okkenhaug
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 11, P: 184-186
  • Gain- and loss-of-function mutations in phosphoinositide 3-kinase-δ (PI3Kδ) result in a primary immunodeficiency syndrome termed APDS. Understanding the function of PI3Kδ in adaptive immune responses — from studies of mouse models of these mutations and from patients with APDS — provides new insights on how mutations in PI3Kδ promote immunodeficiencies.

    • Carrie L. Lucas
    • Anita Chandra
    • Klaus Okkenhaug
    Reviews
    Nature Reviews Immunology
    Volume: 16, P: 702-714